ClinicalTrials.gg
Not yet recruitingNCT07694765Updated Jul 10, 2026

A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of LM-364 for injection and Tislelizumab in Malignant Tumors, sponsored by LaNova Medicines Limited. Not yet recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors.

For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.

02

Conditions studied

  • Malignant Tumors

Browse trials for

03

In context

Neoplasms

10,837 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 90 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who are willing to participate in the study and sign the form (ICF) prior to any procedure.
  2. Participants must be ≥18 years or the legal age of consent at the time of signing the ICF.
  3. (ECOG) performance status of 0-1.
  4. ≥ 3 months.
  5. Adequate organ and bone marrow function as defined by protocol.
  6. Participants who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Participant in any other clinical trial within 28 days prior to 1st dosing of LM-364.
  2. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of v6.0.
  3. Participants with uncontrolled tumour-related pain.
  4. Use of any within 28 days prior to 1st dosing of LM-364.
  5. Participants who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-364.
  6. Participants who have severe cardiovascular disease.
  7. Participants who have uncontrolled or severe illness.
  8. Participants who have a history of immunodeficiency disease.
  9. Participants with a known history of disease.
  10. Participants who have other active which are likely to require the treatment.
  11. female who have positive results in pregnancy test or are lactating.
  12. Participants who have psychiatric illness or disorders that may preclude study compliance.
  13. Participants who is judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    LM-364 Monotherapy

    Drug: LM-364 for injection

  • Experimental
    LM-364 Combination Therapy

    Drug: LM-364 for injection · Drug: Tislelizumab

Interventions

  • DrugLM-364 for injection

    Q3W, Intravenous Drip

  • Q3W, Intravenous Drip

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity (DLT)

    Phase I

    Time frame: 78 weeks

  2. Incidence of Treatment-Emergent Adverse Events (AEs)

    Phase I

    Time frame: 78 weeks

  3. Incidence of serious adverse events (SAEs)

    Phase I

    Time frame: 78 weeks

  4. Temperature (Celsius)

    Phase I

    Time frame: 78 weeks

  5. Pulse in BPM(Beat per Minute)

    Phase I

    Time frame: 78 weeks

  6. Blood Pressure in mmHg

    Phase I

    Time frame: 78 weeks

  7. Weight in Kg

    Phase I

    Time frame: 78 weeks

  8. Height in centimeters

    Phase I

    Time frame: 78 weeks

  9. Blood Routine examination -> Complete Blood Count

    Phase I

    Time frame: 78 weeks

  10. Urine Routine examination ->Urinalysis

    Phase I

    Time frame: 78 weeks

  11. Blood Biochemistry test -> Electrolytes and Metabolic Parameters

    Phase I

    Time frame: 78 weeks

  12. Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT),

    Phase I

    Time frame: 78 weeks

  13. Pregnancy test

    Phase I

    Time frame: 78 weeks

  14. Thyroid Function Test-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)

    Phase I

    Time frame: 78 weeks

  15. Echocardiography- LVEF (Left Ventricular Ejection Fraction) in percentage

    Phase I

    Time frame: 78 weeks

  16. 12-lead electrocardiogram (ECG) in HR

    Phase I

    Time frame: 78 weeks

  17. 12-lead electrocardiogram (ECG) in RR

    Phase I

    Time frame: 78 weeks

  18. 12-lead electrocardiogram (ECG) in QRS

    Phase I

    Time frame: 78 weeks

  19. 12-lead electrocardiogram (ECG) in QT

    Phase I

    Time frame: 78 weeks

  20. 12-lead electrocardiogram (ECG) in QTcF

    Phase I

    Time frame: 78 weeks

  21. ECOG(Eastern Cooperative Oncology Group) score

    Phase I

    Time frame: 78 weeks

  22. Objective Response Rate (ORR)

    Phase II

    Time frame: 130 weeks

Secondary outcomes

  1. Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

    Phase I/II

    Time frame: 130 weeks

  2. PK Parameter:Time of Maximum Observed Concentration (Tmax)

    Phase I/II

    Time frame: 130 weeks

  3. PK Parameter: Area Under the Concentration-time Curve (AUC)

    Phase I/II

    Time frame: 130 weeks

  4. PK Parameter: Steady State Maximum Concentration (Cmax,ss) PK Parameter: Steady State Maximum Concentration(Cmax,ss)

    Phase I/II

    Time frame: 130 weeks

  5. PK Parameter: Steady State Minimum Concentration (Cmin,ss)

    Phase I/II

    Time frame: 130 weeks

  6. PK Parameter: Systemic Clearance at Steady State (CLss)

    Phase I/II

    Time frame: 130 weeks

  7. PK Parameter: Accumulation Ratio (Rac)

    Phase I/II

    Time frame: 130 weeks

  8. PK Parameter: Elimination Half-life (t1/2)

    Phase I/II

    Time frame: 130 weeks

  9. PK Parameter: Volume of Distribution at Steady-State (Vss)

    Phase I/II

    Time frame: 130 weeks

  10. PK Parameter: Degree of Fluctuation (DF)

    Phase I/II

    Time frame: 130 weeks

  11. Immunogenicity testing->Anti-Drug Antibody test

    Phase I/II

    Time frame: 130 weeks

  12. Objective Response Rate (ORR)

    Phase I/II

    Time frame: 130 weeks

  13. Duration of Response (DOR) in Month

    Phase I/II

    Time frame: 130 weeks

  14. Disease control rate (DCR) in percentage

    Phase I/II

    Time frame: 130 weeks

  15. Progression-free survival (PFS) in Month

    Phase I/II

    Time frame: 130 weeks

  16. Overall survival (OS) in Month

    Phase I/II

    Time frame: 130 weeks

  17. Changes of target lesions from baseline in Millimeter

    Phase I/II

    Time frame: 130 weeks

  18. Incidence of adverse events (AEs)

    Phase II

    Time frame: 130 weeks

  19. Incidence of serious adverse events (SAEs)

    Phase II

    Time frame: 130 weeks

  20. Temperature (Celsius)

    Phase II

    Time frame: 130 weeks

  21. Pulse in BPM(Beat per Minute)

    Phase II

    Time frame: 130 weeks

  22. Blood Pressure in mmHg

    Phase II

    Time frame: 130 weeks

  23. Weight in Kg

    Phase II

    Time frame: 130 weeks

  24. Height in centimeters

    Phase II

    Time frame: 130 weeks

  25. Blood Routine examination -> Complete Blood Count

    Phase II

    Time frame: 130 weeks

  26. Urine Routine examination ->Urinalysis

    Phase II

    Time frame: 130 weeks

  27. Blood Biochemistry test -> Electrolytes and Metabolic Parameters

    Phase II

    Time frame: 130 weeks

  28. Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), International normalized ratio (INR)

    Phase II

    Time frame: 130 weeks

  29. Pregnancy test

    Phase II

    Time frame: 130 weeks

  30. Thyroid Function Test-For the detection of thyroid-stimulating hormone (TSH), free

    Phase II

    Time frame: 130 weeks

  31. Echocardiography- LVEF (Left Ventricular Ejection Fraction) in percentage

    Phase II

    Time frame: 130 weeks

  32. ECOG(Eastern Cooperative Oncology Group) score

    Phase II

    Time frame: 130 weeks

  33. 12-lead electrocardiogram (ECG) in HR

    Phase II

    Time frame: 130 weeks

  34. 12-lead electrocardiogram (ECG) in RR

    Phase II

    Time frame: 130 weeks

  35. 12-lead electrocardiogram (ECG) in PR

    Phase II

    Time frame: 130 weeks

  36. 12-lead electrocardiogram (ECG) in QRS

    Phase II

    Time frame: 130 weeks

  37. 12-lead electrocardiogram (ECG) in QT

    Phase II

    Time frame: 130 weeks

  38. 12-lead electrocardiogram (ECG) in QTcF

    Phase II

    Time frame: 130 weeks

  39. Biomarker test -> Tumor tissue biomarker test

    Phase I/II

    Time frame: 130 weeks

  40. QTc-PK relationship -> Correlation concentrations (total antibody, free DXd) vs ΔQTcF (Fridericia's correction)

    Phase I

    Time frame: 12 weeks

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2028, 29 months later.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 29 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Jul 10, 2026
StartEst.
Jul 15, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07694765
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jul 10, 2026

Study contacts

Alex Yuan
Contact
alexyuan@lanovamed.com
+8615901815211

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion